Ahmadi A, Gamboa J, Norman J, Enkhmaa B, Tucker M, Bennett B
Clin J Am Soc Nephrol. 2024; 20(1):12-22.
PMID: 39480994
PMC: 11737449.
DOI: 10.2215/CJN.0000000000000566.
Lewandowski S, El K, Campbell J
Am J Physiol Endocrinol Metab. 2024; 327(1):E103-E110.
PMID: 38775725
PMC: 11390117.
DOI: 10.1152/ajpendo.00360.2023.
Shao Y, Chen Y, Zhu M, Liu Y, Fang C, Wang M
Diabetes Metab Syndr Obes. 2024; 17:1563-1573.
PMID: 38601038
PMC: 11005929.
DOI: 10.2147/DMSO.S457830.
Jakubowska A, le Roux C, Viljoen A
Endocrinol Metab (Seoul). 2024; 39(1):12-22.
PMID: 38356208
PMC: 10901658.
DOI: 10.3803/EnM.2024.1942.
Ahmadi A, Gamboa J, Norman J, Enkhmaa B, Tucker M, Bennett B
medRxiv. 2024; .
PMID: 38196612
PMC: 10775324.
DOI: 10.1101/2023.12.15.23300050.
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.
Folli F, Finzi G, Manfrini R, Galli A, Casiraghi F, Centofanti L
Am J Physiol Endocrinol Metab. 2023; 325(5):E595-E609.
PMID: 37729025
PMC: 10874655.
DOI: 10.1152/ajpendo.00236.2023.
Not the second fiddle: α cell development, identity, and function in health and diabetes.
Brooks E, Sussel L
J Endocrinol. 2023; 258(2).
PMID: 37171828
PMC: 10524258.
DOI: 10.1530/JOE-22-0297.
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases.
Haedersdal S, Andersen A, Knop F, Vilsboll T
Nat Rev Endocrinol. 2023; 19(6):321-335.
PMID: 36932176
DOI: 10.1038/s41574-023-00817-4.
The past, present, and future physiology and pharmacology of glucagon.
Capozzi M, DAlessio D, Campbell J
Cell Metab. 2022; 34(11):1654-1674.
PMID: 36323234
PMC: 9641554.
DOI: 10.1016/j.cmet.2022.10.001.
Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment.
Pelle M, Provenzano M, Zaffina I, Pujia R, Giofre F, Luca S
Life (Basel). 2022; 12(1).
PMID: 35054422
PMC: 8779403.
DOI: 10.3390/life12010029.
Glucagon's Metabolic Action in Health and Disease.
Zeigerer A, Sekar R, Kleinert M, Nason S, Habegger K, Muller T
Compr Physiol. 2021; 11(2):1759-1783.
PMID: 33792899
PMC: 8513137.
DOI: 10.1002/cphy.c200013.
The role of GIP in α-cells and glucagon secretion.
El K, Campbell J
Peptides. 2019; 125:170213.
PMID: 31785304
PMC: 7580028.
DOI: 10.1016/j.peptides.2019.170213.
Incretins in obesity and diabetes.
Chia C, Egan J
Ann N Y Acad Sci. 2019; 1461(1):104-126.
PMID: 31392745
PMC: 10131087.
DOI: 10.1111/nyas.14211.
Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes.
Kawamori D
Diabetol Int. 2019; 8(3):248-256.
PMID: 30603330
PMC: 6224887.
DOI: 10.1007/s13340-017-0327-x.
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T, Sloop K, Loghin C, Alsina-Fernandez J, Urva S, Bokvist K
Mol Metab. 2018; 18:3-14.
PMID: 30473097
PMC: 6308032.
DOI: 10.1016/j.molmet.2018.09.009.
Stimulation of the endogenous incretin glucose-dependent insulinotropic peptide by enteral dextrose improves glucose homeostasis and inflammation in murine endotoxemia.
Shah F, Singamsetty S, Guo L, Chuan B, McDonald S, Cooper B
Transl Res. 2017; 193:1-12.
PMID: 29222967
PMC: 5826869.
DOI: 10.1016/j.trsl.2017.11.001.
Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.
Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Atageldiyeva K, Takiyama Y
Diabetologia. 2015; 59(3):533-41.
PMID: 26693710
DOI: 10.1007/s00125-015-3842-y.
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?.
Godinho R, Mega C, Teixeira-de-Lemos E, Carvalho E, Teixeira F, Fernandes R
J Diabetes Res. 2015; 2015:806979.
PMID: 26075286
PMC: 4449938.
DOI: 10.1155/2015/806979.
Glucagon and type 2 diabetes: the return of the alpha cell.
Lund A, Bagger J, Christensen M, Knop F, Vilsboll T
Curr Diab Rep. 2014; 14(12):555.
PMID: 25344790
DOI: 10.1007/s11892-014-0555-4.
GIP and GLP-1, the two incretin hormones: Similarities and differences.
Seino Y, Fukushima M, Yabe D
J Diabetes Investig. 2014; 1(1-2):8-23.
PMID: 24843404
PMC: 4020673.
DOI: 10.1111/j.2040-1124.2010.00022.x.